

PATENTS AS PROTECTION OF TRADITIONAL MEDICAL KNOWLEDGE?

EUROPEAN STUDIES IN LAW AND ECONOMICS SERIES

1. *Group Litigation in European Competition Law. A Law and Economics Perspective*, Sonja E. Keske
2. *Behavioural Economics in Consumer Policy*, Hanneke Luth
3. *Ex-Post Liability Rules in Modern Patent Law*, Rosa Castro Bernieri
4. *Competition and Innovation in the EU Regulation of Pharmaceuticals: The Case of Parallel Trade*, Claudia Desogus
5. *The Law and Economics of Organ Procurement*, Firat Bilgel
6. *Law and Economics in the RIA World. Improving the use of economic analysis in public policy and legislation*, Andrea Renda
7. *Regulatory Competition in European Corporate and Capital Market Law*, Lars Hornuf
8. *Economic Criteria for Criminalization: Optimizing Enforcement in Case of Environmental Violations*, Katarina Svatikova

PATENTS AS PROTECTION OF
TRADITIONAL MEDICAL
KNOWLEDGE?

A Law and Economics Analysis

Petra EBERMANN



intersentia

Cambridge – Antwerp – Portland

Intersentia Publishing Ltd.
Trinity House | Cambridge Business Park | Cowley Road
Cambridge | CB4 0WZ | United Kingdom
Tel.: +44 1223 393 753 | Email: mail@intersentia.co.uk

Distribution for the UK:
Hart Publishing Ltd.
16C Worcester Place
Oxford OX1 2JW
UK
Tel.: +44 1865 517 530
Email: mail@hartpub.co.uk

Distribution for the USA and Canada:
International Specialized Book Services
920 NE 58th Ave. Suite 300
Portland, OR 97213
USA
Tel.: +1 800 944 6190 (toll free)
Email: info@isbs.com

Distribution for Austria:
Neuer Wissenschaftlicher Verlag
Argentinierstraße 42/6
1040 Wien
Austria
Tel.: +43 1 535 61 03 24
Email: office@nvw.at

Distribution for other countries:
Intersentia Publishing nv
Groenstraat 31
2640 Mortsel
Belgium
Tel.: +32 3 680 15 50
Email: mail@intersentia.be

Patents as Protection of Traditional Medical Knowledge? A Law and Economics
Analysis
Petra Ebermann

© 2012 Intersentia
Cambridge – Antwerp – Portland
www.intersentia.com | www.intersentia.co.uk

ISBN 978-1-78068-073-6
NUR 820

British Library Cataloguing in Publication Data. A catalogue record for this book is
available from the British Library.

No part of this book may be reproduced in any form, by print, photoprint, microfilm or any
other means, without written permission from the publisher.

ACKNOWLEDGMENTS

This book was in large parts written while I was a research assistant at the Institute of Law and Economics at the University of Hamburg. A number of people have contributed to the final success of this project and I want to take the opportunity to thank them.

First of all, I am especially grateful to my supervisor Thomas Eger for his time, helpful comments and advice and likewise to Hans-Bernd Schäfer who kindly agreed to act as second reviewer and handled the review process very efficiently whilst offering appropriate critique. My colleagues at the Institute were supportive at all times and provided well appreciated comments and inspiration. Amongst them, I would like to mention Katharina Greczszuk and Katherine Walker explicitly who have also become good friends of mine during this time. I wish to thank the editors of the scientific series 'European Studies in Law and Economics' for giving me the opportunity to publish this book in this series: Michael G. Faure, Luigi A. Franzoni and Patrick C. Leyens. I thank the Max Planck Institute of Intellectual Property and Competition Law in Munich for allowing me to conduct parts of my research at their library. I am especially indebted to Inga Ebermann and Tanja Friedrich for their active support, valuable comments and advice and Gabor Gottlieb and Paul Stange for providing practical and technical support at all times.

Most importantly, I want to take the opportunity to thank my parents, my sister (once more) and Patrick Hauser for their support, patience, kindness and constant encouragement.

CONTENTS

<i>Acknowledgments</i>	v
Introduction	1
PART 1.	
TRADITIONAL MEDICAL KNOWLEDGE, BIOLOGICAL DIVERSITY AND INTELLECTUAL PROPERTY RIGHTS	9
Chapter 1.	
The Concept of Traditional Medical Knowledge and the Impact of Biotechnology.....	11
1.1. A Definition of Traditional Medical Knowledge	11
1.1.1. Traditional and Indigenous Knowledge	11
1.1.2. Traditional Medical Knowledge.....	13
1.1.3. General Characteristics of Traditional Medical Knowledge	14
1.1.3.1. Traditional Knowledge Holders.....	15
1.1.3.2. Creation and Preservation	15
1.1.3.3. Ownership	15
1.2. The Role of Natural Resources in Pharmaceutical R&D	16
1.2.1. Overview	16
1.2.2. Pharmaceutical Biotechnology.....	17
1.2.3. Bioprospecting Research Project	19
1.3. The Value of Pharmaceutical Biotechnology and Traditional Medical Knowledge	21
1.3.1. The Value of Pharmaceutical Biotechnological R&D.....	21
1.3.2. The Value of Traditional Medical Knowledge	22
Chapter 2.	
The Convention on Biological Diversity	25
2.1. Biological Diversity.....	25
2.1.1. Loss of Biodiversity	25
2.1.2. Consequences of Biodiversity Loss	26
2.2. Main Objectives of the CBD	27
2.2.1. Conservation and Sustainable Use	28

2.2.2.	Access to Biological Resources and Benefit Sharing	30
2.2.2.1.	National Sovereignty	31
2.2.2.2.	The Tragedy of the Commons	32
2.2.2.3.	The Role of Property Rights in Access and Benefit-Sharing Regulation.	33
2.3.	Article 8 (j) CBD	35
2.3.1.	The Elements of Traditional Knowledge Protection.	35
2.3.2.	Relationship with the Objectives	35
2.3.3.	Form of Protection	37
2.3.3.1.	Protection by Intellectual Property Rights.	37
2.3.3.2.	Positive and Negative Approaches to Protection.	38
 Chapter 3.		
	Trade-Related Intellectual Property Rights and Traditional Medical Knowledge.	39
3.1.	The TRIPS Agreement	39
3.1.1.	Introduction	40
3.1.1.1.	The International Legal Developments	40
3.1.1.2.	The Economic Rationale of Intellectual Property Protection	41
3.1.2.	Objectives of the TRIPS Agreement	43
3.1.2.1.	Promotion of Free Trade	44
3.1.2.2.	Promotion of Economic Development	45
3.1.2.3.	Intellectual Property Rights and Developing Countries	47
3.1.3.	General Principles of Non-Discrimination	52
3.1.3.1.	National Treatment	52
3.1.3.2.	Most-Favoured-Nation Clause	52
3.2.	The International Legal and Economic Framework of Patents	53
3.2.1.	Historical Development of Today's Patent Laws	54
3.2.2.	Overview on TRIPS Rules on Patents	54
3.2.2.1.	Patentable Subject Matter	55
3.2.2.2.	Rules on Biotechnological Inventions and Biological Resources	56
3.2.2.3.	Disclosure	57
3.2.3.	The Economic Underlyings of Patenting	57
3.2.3.1.	The Incentive-to-Invent Theory	57
3.2.3.2.	Patent Scope	59
3.3.	The Interaction Between Traditional Medical Knowledge, the TRIPS Agreement and the CBD	61
3.3.1.	Traditional Knowledge in the TRIPS Context.	61
3.3.2.	Intellectual Property Rights and the CBD	62

3.3.2.1.	Article 8 (j) CBD – Preservation of and Respect for the Knowledge, Innovations and Practices of Traditional Communities.	62
3.3.2.2.	Conservation and Sustainable Use of Biodiversity	63
3.3.2.3.	Article 15 CBD – Access to Genetic Resources and Fair and Equitable Benefit Sharing	63
3.3.2.4.	Article 16 CBD – Access to and Transfer of Technology	63
3.4.	Summary of the Main Results of Part 1	64

PART 2.

THE STATUS QUO – PROTECTION OF TRADITIONAL MEDICAL KNOWLEDGE AND BIOTECHNOLOGICAL INVENTIONS UNDER CURRENT PATENT LAW	67
---	----

Chapter 1.

Patentability Criteria in the US and the EU	71
---	----

1.1. Legal Foundations for (Biotechnological) Patents in the US and the EU	72
1.1.1. Sources of US Patent Law	72
1.1.1.1. The Constitution.	72
1.1.1.2. Federal Statutes and Regulations.	72
1.1.1.3. Case Law	73
1.1.2. European Patent Law	74
1.1.2.1. The European Patent Convention	74
1.1.2.2. The Biotechnology Directive	75
1.1.2.3. National Laws and Court Decisions	76
1.2. Substantive Patent Requirements	76
1.2.1. Products of Nature	76
1.2.1.1. US Patent Law	77
1.2.1.2. European Patent Law	79
1.2.2. Novelty	82
1.2.2.1. The State of the Art in US Patent Law.	82
1.2.2.2. The European Approach to Novelty	84
1.2.3. Inventive Step and Non-Obviousness	85
1.2.3.1. US Patent Law – Non-Obviousness.	86
1.2.3.2. European Patent Law – Inventive Step	89
1.2.4. Utility and Industrial Application.	91
1.2.4.1. US – Utility	91
1.2.4.2. EU – Industrial Application	93
1.3. Specification	94
1.3.1. Disclosure of the Invention.	94

1.3.1.1.	US Patent Law	94
1.3.1.2.	Europe	96
1.3.2.	Patent Claims	98
1.3.2.1.	Claim Categories	98
1.3.2.2.	Claim Drafting	98
1.4.	Concluding Remarks	100
Chapter 2.		
	Biotechnological Patents on Pharmaceutical Drugs Developed in Bioprospecting Research Projects	101
2.1.	The Patentability of Biotechnological Inventions Using Traditional Medical Knowledge	101
2.1.1.	Natural Products Doctrine	101
2.1.2.	Traditional Medical Knowledge as Invalidating Prior Art	102
2.1.2.1.	The <i>Neem</i> Patents	103
2.1.2.2.	Analysis of the Prior Art Assessment in the <i>Neem</i> Proceedings	104
2.1.2.3.	The Standard of Disclosure	105
2.1.3.	Non-Obviousness in Bioprospecting Research Projects	106
2.1.3.1.	US Patent Law: The Standard of Non-Obviousness in the Aftermath of <i>KSR</i>	107
2.1.3.2.	The Inventive Step Requirement in Europe: <i>Neem</i> and <i>Hoodia</i>	109
2.2.	Analysis of the Results	112
2.2.1.	The Importance of Patents for Pharmaceutical R&D	112
2.2.2.	The Predictability of the Outcomes of Patent Proceedings	114
Chapter 3.		
	The Rights of the Providers of Traditional Medical Knowledge	117
3.1.	The Patentability of Traditional Medical Knowledge	117
3.1.1.	Products of Nature	117
3.1.2.	Novelty and Non-Obviousness	118
3.1.3.	Formal Requirements	120
3.2.	The Owner of the Patent: The Concept of Joint Inventorship	120
3.2.1.	Legal Definition of Joint Inventorship	121
3.2.1.1.	Requirements for Joint Inventorship in US Patent Law	121
3.2.1.2.	Joint Inventorship Under the EPC	122
3.2.2.	Joint Inventorship of Traditional Knowledge Groups and Pharmaceutical Companies	124
3.3.	Analysis of the Results	127
3.3.1.	The Public Good Problem	127

3.3.1.1. Suboptimal Rate of Innovation	128
3.3.1.2. Free-Riding	129
3.3.2. Allocation of Resources	129
3.3.3. Implementation of the CBD	131
3.3.3.1. Prior Informed Consent	131
3.3.3.2. Benefit Sharing	131
3.3.3.3. Disclosure of the Origin of the Source	132
3.4. Summary of the Main Results of Part 2	132
PART 3.	
PROTECTING AND REWARDING TRADITIONAL MEDICAL	
KNOWLEDGE CONTRIBUTIONS UNDER PROPERTY AND	
LIABILITY REGIMES	
	135
Chapter 1.	
The Property Rights-based Approach to Protection	
	139
1.1. The Construction of Traditional Knowledge Rights	139
1.1.1. Novel Interpretation of Existing Norms	139
1.1.1.1. Invention	140
1.1.1.2. Novelty and Inventive Step	140
1.1.2. Sui Generis Systems – Definition of New Rights for Indigenous	
Peoples	141
1.2. Implementation of Article 8 (j) CBD Through Traditional Knowledge	
Rights	144
1.2.1. Interpretation and Infringement	144
1.2.1.1. Literal Infringement	145
1.2.1.2. The Doctrine of Equivalentents	145
1.2.1.3. Implications for the Right of Traditional Knowledge	
Providers	148
1.2.2. Economic Analysis – The Effects of Patents in Cumulative	
Innovation Scenarios	149
1.2.2.1. Optimal Allocation of Rights and Division of Profits ..	149
1.2.2.2. Hold-Up and Anticommons	151
1.2.2.3. Conclusion	153
1.3. Co-Operation Between Indigenous Groups and Pharmaceutical	
Companies and Joint Inventorship	154
1.3.1. Modification of the Requirements	154
1.3.2. The Rights of Joint Inventors	155
1.3.2.1. Use of the Patented Invention	155
1.3.2.2. Sharing of Profits	156
1.3.2.3. Discussion	156
1.4. Conclusion on the Property Rights Approach	157

Chapter 2.	
Benefit-Sharing Agreements and Liability Rules	159
2.1. Mandatory Benefit-Sharing Agreements as Conditions to Patentability	160
2.2. Benefit Sharing Under a Liability-Based Approach.	161
2.2.1. Conditions of a Compensatory Liability Regime	162
2.2.2. Determination of the Value.	163
2.2.2.1. Statutory Rules	164
2.2.2.2. Collective Rights Organizations	164
2.2.3. Impact of Benefit Sharing on Retail Costs of Pharmaceuticals. . .	165
2.3. Conclusion on Benefit Sharing	167
 Chapter 3.	
Prior Informed Consent and Disclosure Requirements	169
3.1. The Content and Scope of the Requirements	169
3.1.1. Prior Informed Consent Requirement	169
3.1.2. Disclosure Requirements.	170
3.1.3. Effects and Costs of Prior Informed Consent and Disclosure Requirements.	170
3.1.3.1. The Sanction in Case of Non-Compliance.	170
3.1.3.2. The Effects of Disclosure Requirements	171
3.1.3.3. The Effects of Prior Informed Consent	172
3.2.. Compatibility with TRIPS.	172
3.2.1. Prior Informed Consent	173
3.2.2. Disclosure Requirements.	173
3.2.2.1. Substantive or Formal Requirements	173
3.2.2.2. Article 29 TRIPS.	173
3.2.2.3. Article 62 TRIPS.	174
3.3. Conclusion on Disclosure and Prior Informed Consent Requirements.	175
3.4. Summary of the Results of Part 3.	175
 Conclusion. The Results of the Analysis and the Implications for Future Discussions	177
 <i>Bibliography</i>	185
 <i>List of Cases</i>	193
 <i>About the author</i>	197
 <i>About the series</i>	199